Company intelligence / Profile preview

Lijun International Pharmaceutical

Shijiazhuang, Hebei, China

Ownership: Private
Employees: ~3600
Development stage: Other

Overview

The company is China’s largest manufacturer of macrolide antibiotics, maintains leadership in intravenous infusion solutions for hospital use, and produces a diverse portfolio of antibiotics, infusions, and select non-antibiotic finished medicines, with Chinese FDA and US FDA approval on several products. Enerxin Capsule was recognized as effective against Influenza A (H1N1)[3][5][8].

Therapeutic areas: ImmunologyInfectious DiseasesCardiovascular
Modalities: Small moleculeBiologicModern Chinese traditional medicine
Industry: Pharma

Beyond the preview

Go deeper on Lijun International Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lijun International Pharmaceutical.

Explore the full profile